PCE Home Study
New Treatment Paradigms in Relapsed/Refractory Multiple Myeloma: Integrating Novel Agents Into Clinical Practice
Release Date: August 15, 2020
Expiration Date: August 14, 2021
CE/CME Credit Hours: 1.00
Pharmacology Credit Hours: 1.00
Begin »
program overview
Program Description
While relapse is inevitable in multiple myeloma (MM), current treatment strategies prolong response duration and progression-free survival at each step of care. With longer survival comes the need to proactively manage disease- and treatment-related toxicities, and with oral therapies, the need to maintain adherence with sometimes complicated dosing schedules.
Format
eNewsletter with interactive benchmarking
Learning Objectives
After completing this activity, participants should be better able to:
- Identify novel agents used in the treatment of relapsed/refractory (RR) MM and guideline recommendations for their use
- Apply established criteria to identify patients who have developed RRMM and individualize therapy based on relevant patient- and disease-related characteristics
- Use current recommendations for monitoring and managing treatment-related adverse events in patients with RRMM
Target Audience
Oncology NPs, PAs, and nurses
Faculty
Pritesh Patel, MD
- Associate Professor of Clinical Medicine
- Division of Hematology-Oncology
- Associate Director
- Blood and Marrow Transplant Program
- University of Illinois at Chicago
- Chicago, Illinois
DETAILS
Joint Accreditation Statement
In support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
ANCC Credit Designation
Course director: Lee Schwartzberg, MD, FACP, West Cancer Center, Germantown, Tennessee
CNE course advisor: Beth Sandy, MSN, CRNP, Abramson Cancer Center, Philadelphia, Pennsylvania
Nursing contact hours: 1.00, which includes 1.00 hour of pharmacology credit
AAPA Credit Designation
Practicing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credit. Approval is valid until August 14, 2021. PAs should only claim credit commensurate with the extent of their participation.
PA course advisor: Corinne Williams, PA-C, Northwestern University Feinberg School of Medicine, Chicago, Illinois
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change.
This program was developed from a series of programs cosupported by educational grants from Astellas; Astellas and Pfizer; Celgene Corporation; Exelixis; GlaxoSmithKline; Karyopharm Therapeutics; Merck & Co., Inc.; Pharmacyclics LLC, an AbbVie Company; Sanofi Genzyme; Seattle Genetics; and Verastem Oncology.
This activity is supported by an educational grant from Celgene Corporation, GlaxoSmithKline, Sanofi Genzyme, and Karyopharm Therapeutics.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange are required to disclose to the audience any relevant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Patel: speakers bureau: Amgen, Celgene, Janssen.
Ms Sandy: speakers bureau: AstraZeneca, Merck, Takeda.
Dr Schwartzberg: consultant: Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Pfizer, Spectrum.
Ms Williams: speakers bureau: AstraZeneca.
None of the members of the PCE staff have any relevant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the content in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
Release date: August 15, 2020
Expiration date: August 14, 2021
For Practicing Clinicians Exchange general information, contact pce@practicingclinicians.com.
© 2020 Practicing Clinicians Exchange. All Rights Reserved. 97520OPCE-7E